2023年ASCO非小细胞肺癌靶向和免疫治疗进展

Research progress on targeted therapy and immunotherapy of non-small-cell lung cancer at 2023 ASCO annual meeting

肺癌领域的研究进展日新月异。随着分子检测技术的进步,肺癌的驱动基因图谱日渐细化,致癌分子机制及免疫逃逸机制的研究也逐步深入,靶向或免疫药物的开发和优化路径趋于成熟。作为肿瘤学顶尖学术会议,美国临床肿瘤学会(American Society of Clinical Oncology,ASCO)年会每年汇集大批肿瘤学专家共同探讨肿瘤学领域的最新进展。本文主要聚焦非小细胞肺癌(non-small-cell lung cancer,NSCLC),拟从靶向治疗和免疫治疗两个方面对2023年ASCO大会报道的NSCLC研究进展进行重点摘述和讨论。

The research in lung cancer is progressing with each passing day.With the progress of molecular detection technology,the driver gene map of lung cancer is increasingly refined,the research on carcinogenic molecular mechanism and immune escape mechanism is gradually deepened,and the path of targeted or immunotherapy drug development and optimization is becoming mature.As the leading academic conference in oncology,the annual meeting of the American Society of Clinical Oncology(ASCO)brings together a large number of oncology experts each year to discuss the latest advances in the field of oncology.This paper mainly focuses on non-small-cell lung cancer(NSCLC),and intends to summarize and discuss the important research progress of NSCLC reported at the 2023 ASCO annual meeting from the aspects of targeted therapy and immunotherapy.